☰

Jodi A. McKenzie, Ph.D. - Publications

Affiliations: 
2012 Oncological Sciences University of Utah, Salt Lake City, UT 
Area:
Molecular Biology, Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, et al. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. Journal For Immunotherapy of Cancer. 9. PMID 33589527 DOI: 10.1136/jitc-2020-001819  0.386
2020 Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, et al. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy : Cii. PMID 33123754 DOI: 10.1007/s00262-020-02748-9  0.542
2019 Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson H, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, et al. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31371342 DOI: 10.1158/1078-0432.Ccr-19-1259  0.551
2018 Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/J.Cmet.2018.02.024  0.592
2018 Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29496759 DOI: 10.1158/1078-0432.Ccr-17-2483  0.355
2017 McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, et al. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 29267866 DOI: 10.1093/Jnci/Djx257  0.514
2017 Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/S41467-017-00449-Z  0.531
2017 Huang L, Wang Z, Liu C, Xu C, Mbofung RM, McKenzie JA, Khong H, Hwu P, Peng W. CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene. PMID 28263973 DOI: 10.1038/Onc.2017.35  0.513
2016 Peng W, McKenzie JA, Hwu P. Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity. Cancer Discovery. 6: 953-5. PMID 27587467 DOI: 10.1158/2159-8290.Cd-16-0698  0.466
2016 McKenzie JA, Mbofung RM, Malu S, Hwu P. Abstract B152: Increasing the antitumor efficacy of immunotherapy in melanoma by using topoisomerase I inhibitors Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B152  0.625
2016 Williams L, Malu S, McKenzie J, Mbofung R, Roszik J, Hwu P. Abstract B118: Using a high throughput T-cell cytotoxicity assay to develop combination strategies for immunotherapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B118  0.568
2016 McKenzie JA, Mbofung RM, Malu S, Amaria RN, Ashkin EL, Devi SN, Peng W, Williams LJ, Davis RE, Roszik J, Tieu TN, Heffernan T, Hwu P. Abstract B110: Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B110  0.62
2016 Mbofung RM, McKenzie JA, Malu S, Liu C, Peng W, Kuiatse I, Williams L, Devi S, Wang Z, Tieu T, Heffernan T, Davis RE, Amaria R, Hwu P. Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B105  0.608
2016 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363  0.58
2016 Mbofung RM, McKenzie JA, Malu S, Liu C, Williams L, Peng W, Wang Z, Tripathi S, Tieu T, Zhao S, Devi S, Kuiatse I, Ashkin E, Bailey L, Roszik J, et al. Abstract 4360: Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes Cancer Research. 76: 4360-4360. DOI: 10.1158/1538-7445.Am2016-4360  0.595
2016 Williams L, Malu S, McKenzie J, Mbofung R, Forget M, Bernatchez C, Hwu P. Abstract 4010: Identification of novel targeted and immunotherapy combinations by a high throughput assay of T cell-mediated cytotoxicity Immunology. 76: 4010-4010. DOI: 10.1158/1538-7445.Am2016-4010  0.419
2016 McKenzie JA, Mbofung RM, Malu S, Amaria RN, Davis RE, Zhang L, Tieu TN, Heffernan TP, Hwu P. Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 Cancer Research. 76: 4002-4002. DOI: 10.1158/1538-7445.Am2016-4002  0.634
2016 Wang Z, Malu S, Peng W, McKenzie J, Mbofung R, Williams L, Seth S, Heffernan T, Hwu P. Abstract 1441: Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens Cancer Research. 76: 1441-1441. DOI: 10.1158/1538-7445.Am2016-1441  0.555
2015 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283  0.577
2013 McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D. Survivin promotion of melanoma metastasis requires upregulation of α5 integrin Carcinogenesis. 34: 2137-2144. PMID 23640047 DOI: 10.1093/Carcin/Bgt155  0.603
2012 Mckenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma Anticancer Research. 32: 397-404. PMID 22287725  0.535
2010 McKenzie JA, Liu T, Goodson AG, Grossman D. Survivin enhances motility of melanoma cells by supporting Akt activation and α5 integrin upregulation Cancer Research. 70: 7927-7937. PMID 20807805 DOI: 10.1158/0008-5472.Can-10-0194  0.574
Show low-probability matches.